Epithalon vs NAD+
Both compounds are investigated in aging-biology research, but they engage different biological axes and come from different research traditions. Epithalon targets telomerase-activity and pineal-gland biology from Russian gerontology. NAD+ targets the cellular redox and sirtuin/PARP substrate axis from Western metabolic-aging research. This page summarises how the published research separates them.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Compound class | Synthetic tetrapeptide (Ala-Glu-Asp-Gly) | Small-molecule coenzyme (nicotinamide adenine dinucleotide, oxidised form) |
| Best-studied mechanism | Telomerase-activity modulation, pineal-gland function, lifespan endpoints | Cellular redox cofactor, sirtuin and PARP enzyme substrate, NAD+-pool maintenance |
| Research tradition | Russian gerontology (Khavinson, Anisimov laboratories) | Western metabolic-aging biology (Sinclair, Imai, Guarente laboratories) |
| Primary model systems | Murine and Drosophila lifespan studies, neuronal differentiation | Aged rodent NAD+-pool studies, NR/NMN precursor clinical trials in humans |
| Clinical evidence | Small number of Russian clinical-pilot reports (not Phase 1 by Western standards) | Phase 1 dose-ranging for NR and NMN precursors (100-2000 mg/day oral); limited for direct NAD+ |
| Supply format | 10 mg lyophilised peptide vial | 100 mg lyophilised small-molecule vial |
| Reconstitution | Bacteriostatic water | Appropriate solvent; pH and oxidation sensitive |
How they differ in mechanism
Epithalon targets the pineal-gland and telomerase-activity axis. The published mechanistic literature from the Khavinson and Anisimov laboratories describes lifespan-extension effects in murine and Drosophila models with chronic dosing at low microgram-per-animal doses. A secondary line of investigation examines neuronal-differentiation effects and neurotrophic-factor expression. The per-animal dose convention in the Russian gerontology literature complicates direct comparison with Western per-kilogram dose conventions.
NAD+ targets the cellular redox machinery at the core of energy metabolism. It serves as a substrate for the sirtuin enzymes (regulating chromatin modification and metabolic gene expression) and for PARP enzymes (regulating DNA repair). The published research focuses on NAD+-pool decline with age and on maintenance or restoration through direct NAD+ supplementation or precursor administration (NR, NMN). The precursor literature has advanced further clinically than the direct-NAD+ literature.
The two approaches share the aging-biology framing but operate through entirely different biological machinery. Epithalon modulates a nuclear-encoded anti-aging programme via pineal-gland signalling. NAD+ maintains a core metabolic-cofactor pool that declines with age. Investigators interested in aging biology read both literatures but from different mechanistic perspectives, and combined-administration studies are absent from the published record.
How research has examined each
The Epithalon literature is concentrated in Russian gerontology outputs. The Khavinson 2000 Drosophila lifespan study, the Anisimov 2003 mouse lifespan study, and the neuronal-differentiation work form the core of the published research. The literature is small relative to the NAD+ field and is concentrated among a small number of lead investigators.
The NAD+ and precursor literature is broad. The Mills 2016 NMN administration work, the Tarrago 2018 CD38-inhibitor work, and the Phase 1 NR/NMN dose-ranging trials in adult humans form a substantial evidence base. The NNMT-inhibitor literature (5-Amino-1MQ) extends the NAD+-related research ecosystem. The research community is large, internationally distributed, and well-funded.
The two literatures do not cite one another. They occupy non-overlapping research traditions, journals, and conceptual frameworks. Survey reviews of anti-aging interventions may mention both alongside calorie restriction, rapamycin, metformin, and MOTS-c as a class, but the primary research outputs are entirely separate.
Stacking considerations in research contexts
The two compounds are not commonly co-administered in published research. Their biological axes are non-overlapping and no combined-administration hypothesis has been tested in the indexed literature. Both are available as separate vials in the Ronin catalog.
Sourcing both at Ronin
Epithalon ships as a 10 mg lyophilised peptide vial. NAD+ ships as a 100 mg lyophilised vial. Both include certificate-of-analysis documentation. The Epithalon vial page and the NAD+ vial page carry per-compound spec sheets. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.
Frequently asked research questions
Are they both ‘anti-aging compounds’?
Both are investigated in aging-biology research, but through entirely different biological axes: telomerase/pineal for Epithalon, redox-cofactor/sirtuin-PARP for NAD+.
Which has more clinical evidence?
NAD+ precursors (NR, NMN) have Phase 1 dose-ranging data in adult humans. Epithalon has a small number of Russian clinical-pilot reports that do not constitute Phase 1 trials by Western standards.
Do the research traditions overlap?
No. Epithalon is concentrated in Russian gerontology. NAD+ research is international and spans many laboratories. The two literatures do not cite one another.
Are they stacked?
No combined-administration studies appear in the published literature. Both are available as separate vials.
Are either approved for human use?
Neither is approved by the FDA or Health Canada as a human therapeutic under these names. Both are research-grade reagents.
References
- Khavinson VKh et al. Effect of epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development, 2000. [PMID 11087911]
- Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 2003. [PMID 12049808]
- Mills KF et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism, 2016. [PMID 27818143]
- Tarrago MG et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD+ decline. Cell Metabolism, 2018. [PMID 29719226]
- Hong S et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nature Medicine, 2015. [PMID 26011344]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.